- Home
- UAA vs PTGX Comparison
UAA vs PTGX Comparison
Compare UAA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAA
- PTGX
- Stock Information
- Founded
- UAA 1996
- PTGX 2006
- Country
- UAA United States
- PTGX United States
- Employees
- UAA N/A
- PTGX N/A
- Industry
- UAA Apparel
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- UAA Consumer Discretionary
- PTGX Health Care
- Exchange
- UAA Nasdaq
- PTGX Nasdaq
- Market Cap
- UAA 2.5B
- PTGX 2.9B
- IPO Year
- UAA N/A
- PTGX 2016
- Fundamental
- Price
- UAA $7.03
- PTGX $53.34
- Analyst Decision
- UAA Hold
- PTGX Strong Buy
- Analyst Count
- UAA 18
- PTGX 9
- Target Price
- UAA $7.27
- PTGX $67.11
- AVG Volume (30 Days)
- UAA 10.6M
- PTGX 898.5K
- Earning Date
- UAA 08-07-2025
- PTGX 08-05-2025
- Dividend Yield
- UAA N/A
- PTGX N/A
- EPS Growth
- UAA N/A
- PTGX N/A
- EPS
- UAA N/A
- PTGX 0.86
- Revenue
- UAA $5,164,310,000.00
- PTGX $207,801,000.00
- Revenue This Year
- UAA N/A
- PTGX N/A
- Revenue Next Year
- UAA $2.72
- PTGX $47.15
- P/E Ratio
- UAA N/A
- PTGX $62.27
- Revenue Growth
- UAA N/A
- PTGX N/A
- 52 Week Low
- UAA $4.78
- PTGX $30.67
- 52 Week High
- UAA $11.89
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- UAA 59.47
- PTGX 58.33
- Support Level
- UAA $6.15
- PTGX $54.48
- Resistance Level
- UAA $7.17
- PTGX $57.18
- Average True Range (ATR)
- UAA 0.28
- PTGX 2.04
- MACD
- UAA -0.04
- PTGX -0.09
- Stochastic Oscillator
- UAA 86.27
- PTGX 57.13
About UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.